AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the ...

Intervention/Treatment: The study tests AZD6234, an experimental drug administered through weekly subcutaneous injections. It is designed to work alongside existing GLP-1 RA therapy to improve ...

The completion of this study could positively impact AstraZeneca’s stock performance by enhancing investor confidence in their oncology pipeline. As the company continues to innovate in cancer ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

NHS England has poured investment into hospitals while neglecting other parts of the service, Lord Ara Darzi concluded last year in his report on a “broken system”. The share of the UK health budget ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

AstraZeneca CEO Pascal Soriot told Italy’s La Repubblica at the time that its agreement with the EU was “not a contractual commitment. It’s a best effort,” referring to language used in ...